US biotech Paragon Therapeutics yesterday revealed that biotech industry veteran Susanna High has been appointed as chief executive (CEO). In this newly-created role, Ms High will lead the team’s continued efforts to propel the development of a pipeline of transformative therapies and accelerate their potential impact. 22 November 2024
US biotech major Amgen has announced that Dr Howard Chang will join the company as senior vice president of research, effective December 16, 2024. 21 November 2024
New York-based Mind Medicine, a company developing MM120, a form of LSD (lysergide d-tartrate), for mental health conditions, has announced the appointment of Gregg Pratt, as chief regulatory and quality assurance officer. 19 November 2024
Belgian biotech start-up ExeVir Bio says it has appointed Michael Garrett as its new chief executive (CEO), effective 1 December 2024. 18 November 2024
ALX Oncology Holdings, a Californian immuno-oncology company, has announced the appointment of Alan Sandler as chief medical officer (CMO). 14 November 2024
US ophthalmology specialist Ocular Therapeutix announced that Namrata Saroj has joined the Company on a full-time basis as chief business officer (CBO). Dr Saroj previously served as development strategy consultant to Ocular since February 2024. 14 November 2024
VarmX, a Dutch biotech developing innovative approaches for the bypass of direct oral anticoagulants targeting activated factor Xa (FXa DOACs) and inherited coagulation disorders, has appointed industry veteran John Glasspool (pictured, above) as chief executive. 12 November 2024
French biotech DiogenX, which is focused on regenerating insulin-producing beta cells for the treatment of diabetes, today announces the appointment of Dr Klara Owen as chief medical officer. 12 November 2024
Rubedo Life Sciences, a US biopharma developing first-in-class therapies targeting senescent cells which drive age-related diseases, has announced the appointment of Frederick C Beddingfield III, as chief executive officer and board director. 11 November 2024
US clinical-stage drug developer Acumen Pharmaceuticals has appointed Amy Schacterle as chief regulatory officer and head of quality, reporting to Jim Doherty, president and chief development officer at Acumen. 7 November 2024
Memo Therapeutics, a privately-held Swiss biotech company translating unique responses into superior medicines to treat viral infections and cancer, has appointed a new chief development officer (CDO). 4 November 2024
Netherlands-based Tessellate BIO, a pre-clinical stage biotech with a focus on novel synthetic lethality approaches, today announced the appointment of Dr Lara Boyd as chief business officer. 4 November 2024
Fennec Pharmaceuticals has announced the addition of three new executives to bolster its leadership team as the company prepares for expanded commercial operations. 28 October 2024
Emirati company Julphar, one of the largest pharmaceutical manufacturers in the Middle East and North Africa (MENA), has announced the appointment of new executives to help guide the company towards profitability and long-term success. 22 July 2019
Julian Gilbert, the founder of Anglo-American company Acacia Pharma Group, is to step down from his role as chief executive and director at the end of the month. 18 July 2019
Gilead Sciences announced today that John McHutchison, chief scientific officer and head of R&D, has decided to leave the company, effective next month. 17 July 2019
US biotech major Gilead Sciences has lured high pharma profile Christi Shaw to the company as chief executive of CAR-T cancer therapy specialist Kite. 12 July 2019
US RNAi therapies specialist Alnylam yesterday announced that Jeff Poulton joined the company on July 11, 2019, and has been appointed executive vice president and chief financial officer (CFO), effective August 13. 12 July 2019
Privately-held German biotech firm Immatics Biotechnologies today announced that Harpreet Singh has been appointed the company’s chief executive (CEO). 8 July 2019
After the failure of its latest drug candidate in clinical trials, US oncology specialist Merrimack Pharmaceuticals has issued a document to the US Securities and Exchange Commission, announcing the departure of the company’s top two executives. 4 July 2019
French nanomedicine company Nanobiotix today announced organizational changes to align with strategic priorities post European market approval for Hensify (NBTXR3), which was cleared for marketing in April. 1 July 2019
Ever since Dr Scott Gottlieb unexpectedly stepped down as head of the US Food and Drug Administration in March this year, less than two years into his tenure, there has been speculation about where he would re-appear 28 June 2019
USA-based antibacterial products developer Entasis Therapeutics has announced the appointment of David Meek, currently chief executive of French pharma company Ipsen, as chairman of the board of directors, effective immediately. 25 June 2019
German drugmaker Stada Arzneimittel has nominated a successor for Enrique Häusermann, the long-time general manager of its Italian unit EG SpA. 20 June 2019
Valo Therapeutics, a cancer immunotherapy company developing neoantigen-coated oncolytic viruses as therapeutic vaccines, has appointed Dr Michael Stein to the full-time role of chief executive, having served as part-time co-chairman since inception in January 2017. 17 June 2019
Privately-held Akrevia Therapeutics today announced that Joseph Farmer has been appointed as chief operating officer of the biopharma company launched by Atlas Ventures and F-Prime last September. 13 June 2019
California-based rare diseases specialist Eiger BioPharmaceuticals today announced the appointment of Mark Mannebach, as vice president of global regulatory affairs. 10 June 2019
UK developer of inhaled therapeutics Vectura today announces that James Ward-Lilley will be stepping down from the Board and his position as chief executive on June 30, 2019. 10 June 2019
In a surprise announcement, French pharma major Sanofi has revealed that chief executive Olivier Brandicourt will retire in September, to be replaced by Novartis’ current pharma chief, Paul Hudson. 7 June 2019
Pfizer has announced that Jeff Settleman has joined the company as senior vice president and group head of Oncology Research and Development. 6 June 2019
After 20 years in various leadership roles with US pharma major Eli Lilly, Pete Salzmann has left to take the top job at a company specializing in autoimmune diseases. 6 June 2019